Caplin Point Laboratories (BOM:524742) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Caplin Point Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Caplin Point Laboratories's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Caplin Point Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Caplin Point Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories LT-Debt-to-Total-Asset Chart

Caplin Point Laboratories Annual Data

Trend

Jun15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Caplin Point Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Caplin Point Laboratories LT-Debt-to-Total-Asset Calculation

Caplin Point Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	9.2	/	26973.8
	=	0.00

Caplin Point Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	9.2	/	26973.8
	=	0.00

Caplin Point Laboratories (BOM:524742) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Caplin Point Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Caplin Point Laboratories (BOM:524742) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

CAPLIPOINT:India

Address

Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096

Website

https://www.caplinpoint.net

Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines